Clinical trial
Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous…
NCT00442455 · Grupo de Investigación Clínica en Oncología Radioterapia, Other · Completed
Key facts
| NCT number | NCT00442455 |
|---|---|
| Title | Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck |
| Official title | Phase I/II Trial of Erlotinib, Radiation Therapy, and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | Grupo de Investigación Clínica en Oncología Radioterapia, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Squamous Cell Carcinoma of the Head and Neck |
| Intervention type | Drug, Procedure |
| Interventions | Erlotinib chlorhydrate, Cisplatin, Radiation therapy |
| Enrollment | 53 |
| Start date | Jan 1, 2006 |
| Primary completion | Aug 1, 2015 |
| Completion | Aug 1, 2015 |
| First posted | Mar 2, 2007 |
| Last update posted | Jun 6, 2019 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: